BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012;118:2385-93. [PMID: 21953213 DOI: 10.1002/cncr.26555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 2012;30:2179-82. [PMID: 22614986 DOI: 10.1200/JCO.2012.42.0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
2 Wilson FR, Coombes ME, Brezden-Masley C, Yurchenko M, Wylie Q, Douma R, Varu A, Hutton B, Skidmore B, Cameron C. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev 2018;7:191. [PMID: 30428932 DOI: 10.1186/s13643-018-0854-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Ahn ER, Wang E, Glück S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 2012;6:191-207. [PMID: 23226023 DOI: 10.4137/BCBCR.S9301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
4 Wu YT, Xu Z, Arshad B, Wu JS, Zhang K, Wu H, Li X, Li H, Li YC, Wang ZL, Wu KN, Kong LQ. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials. J Cancer 2018;9:3168-76. [PMID: 30210640 DOI: 10.7150/jca.24701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 He X, Dai X, Ji J, Liu H, Shi G, Yeung SJ. Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin Breast Cancer 2021:S1526-8209(21)00136-1. [PMID: 34312098 DOI: 10.1016/j.clbc.2021.05.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Ann Surg Oncol 2021;28:2111-9. [PMID: 33486641 DOI: 10.1245/s10434-020-09480-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123-40. [PMID: 26712595 DOI: 10.1007/s11739-015-1362-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
8 Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol 2013;139:1229-40. [PMID: 23604446 DOI: 10.1007/s00432-013-1436-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Pernas S, Gil-gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-tejedor A, López-ojeda A, Falo C, Fernandez-otega A, Mesia C, Pérez-martin FJ, Urruticoechea A, Germà JR. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Breast Cancer Res Treat 2012;134:1161-8. [DOI: 10.1007/s10549-012-2149-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
10 Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol 2015;95:88-104. [PMID: 25900915 DOI: 10.1016/j.critrevonc.2015.02.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
11 Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. Front Oncol 2021;11:686591. [PMID: 34168999 DOI: 10.3389/fonc.2021.686591] [Reference Citation Analysis]
12 Salmon R, Ceugnart L, Selz J, Hennequin C, Ettore F, Gonçalves A. Les traitements néoadjuvants TNA (RPC 2013). Oncologie 2013;15:607-34. [DOI: 10.1007/s10269-013-2348-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Dent S, Oyan B, Honig A, Mano M, Howell S. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev. 2013;39:622-631. [PMID: 23434074 DOI: 10.1016/j.ctrv.2013.01.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
14 Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 2016;16:352. [PMID: 27259714 DOI: 10.1186/s12885-016-2385-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 12.5] [Reference Citation Analysis]
15 Cirier J, Body G, Jourdan ML, Bedouet L, Fleurier C, Pilloy J, Arbion F, Ouldamer L. [Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype]. Gynecol Obstet Fertil Senol 2017;45:535-44. [PMID: 28939364 DOI: 10.1016/j.gofs.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
16 Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. The Lancet Oncology 2017;18:917-28. [DOI: 10.1016/s1470-2045(17)30434-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 24] [Article Influence: 11.4] [Reference Citation Analysis]
17 von Minckwitz G, Colleoni M, Kolberg H, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. The Lancet Oncology 2018;19:987-98. [DOI: 10.1016/s1470-2045(18)30241-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
18 Echavarria I, Granja M, Bueno C, Lopez-Tarruella S, Peinado P, Sotelo M, Jerez Y, Moreno F, Torres G, Lobo M, Marquez-Rodas I, Del Monte-Millan M, Martín M, García-Saenz JA. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat 2017;162:181-9. [PMID: 28040858 DOI: 10.1007/s10549-016-4098-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. Breast Care (Basel) 2016;11:323-7. [PMID: 27920624 DOI: 10.1159/000452079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer 2015;112:630-5. [PMID: 25584488 DOI: 10.1038/bjc.2014.647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, Siesling S, Lobbes MBI, Smidt ML. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Ann Surg 2020;271:574-80. [PMID: 30557203 DOI: 10.1097/SLA.0000000000003126] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 12.5] [Reference Citation Analysis]
22 Truong J, Lee E, Trudeau M, Chan K. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Annals of Oncology 2016;27:608-18. [DOI: 10.1093/annonc/mdv619] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
23 Komguem L, Guilbert P, Doublier M, Guillemin F. [Evaluation of breast HER2+ cancer pathologic response after a taxan plus trastuzumab-based chemotherapy]. Gynecol Obstet Fertil 2016;44:396-402. [PMID: 27451068 DOI: 10.1016/j.gyobfe.2016.06.007] [Reference Citation Analysis]
24 Biswas T, Jindal C, Fitzgerald TL, Efird JT. Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Int J Environ Res Public Health 2019;16:E124. [PMID: 30621221 DOI: 10.3390/ijerph16010124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2016;2:508-16. [PMID: 26720612 DOI: 10.1001/jamaoncol.2015.4935] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 9.5] [Reference Citation Analysis]
26 Weiss RE, Xia X, Zhang N, Wang H, Chi E. Bayesian methods for analysis of biosimilar phase III trials. Stat Med 2018;37:2938-53. [PMID: 29797335 DOI: 10.1002/sim.7814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Zardawi SJ, Nordman I, Zdenkowski N. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens. Cancer Rep (Hoboken) 2020;3:e1266. [PMID: 32761893 DOI: 10.1002/cnr2.1266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. J Carcinog 2019;18:5. [PMID: 31949426 DOI: 10.4103/jcar.JCar_14_19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Rea D, Tomlins A, Francis A. Time to stop operating on breast cancer patients with pathological complete response? European Journal of Surgical Oncology (EJSO) 2013;39:924-30. [DOI: 10.1016/j.ejso.2013.06.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
30 Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, Kong LQ. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. Ther Clin Risk Manag 2018;14:1789-97. [PMID: 30310287 DOI: 10.2147/TCRM.S176214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gonçalves A. [Not Available]. Bull Cancer 2016;103:S76-89. [PMID: 27494978 DOI: 10.1016/S0007-4551(16)30149-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget 2015;6:18683-92. [PMID: 26084292 DOI: 10.18632/oncotarget.4337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
33 Xu Q, Yuanyuan L, Jiejing Z, Jian L, Qingyu L, Lingya C, Ying L, Changchen S, Yangling L, Wei Y. Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Eff Resour Alloc 2021;19:11. [PMID: 33622356 DOI: 10.1186/s12962-021-00264-w] [Reference Citation Analysis]
34 van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1630-40. [PMID: 30413379 DOI: 10.1016/S1470-2045(18)30570-9] [Cited by in Crossref: 69] [Cited by in F6Publishing: 34] [Article Influence: 17.3] [Reference Citation Analysis]
35 Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, Digiovanna MP, Pusztai L. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer. Breast Cancer Res Treat 2018;169:333-40. [DOI: 10.1007/s10549-017-4653-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
36 Schmidt H, Zhaveri S, Valente C, Pisapati K, Pickholz E, Weltz S, Nayak A, Oza T, Corben A, Weltz C, Port E, Jaffer S. Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer. Breast J 2021;27:120-5. [PMID: 33393166 DOI: 10.1111/tbj.14125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zetterlund L, Celebioglu F, Hatschek T, Frisell J, de Boniface J. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status. Br J Surg 2021;108:583-9. [PMID: 34043772 DOI: 10.1002/bjs.11963] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747-756. [PMID: 24794243 DOI: 10.1016/s1470-2045(14)70160-3] [Cited by in Crossref: 470] [Cited by in F6Publishing: 228] [Article Influence: 58.8] [Reference Citation Analysis]
39 Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg 2017;152:665-70. [PMID: 28423171 DOI: 10.1001/jamasurg.2017.0562] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 14.8] [Reference Citation Analysis]
40 Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Li X, Torres M, O'Regan RM; Georgia Center for Oncology Research and Education. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer 2015;15:31-6. [PMID: 25065563 DOI: 10.1016/j.clbc.2014.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]